Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, and that is more or less 9.11 % above the present share price of $76.07.
Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the earliest quarter of 2021.
The analysts priced targets range from a high of hundred one dolars to a low of $61.
In its newest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is $99.57 billion.
Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with four stars on a 0-5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The retail or Long Term Care segment has selling of prescription drugs as well as assortment of general merchandise.
The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products as well as related services, which includes medical, pharmacy, dental, behavioural health, medical management abilities. The Corporate segment involves in offering management and administrative services. The company was developed by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.